Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

PURPOSE: Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant tumors. We investigated the efficacy of erlotinib alone or in combination with chemotherapy in patients with these characte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jänne, Pasi A., Wang, Xiaofei, Socinski, Mark A., Crawford, Jeffrey, Stinchcombe, Thomas E., Gu, Lin, Capelletti, Marzia, Edelman, Martin J., Villalona-Calero, Miguel A., Kratzke, Robert, Vokes, Everett E., Miller, Vincent A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2012
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397694/
https://ncbi.nlm.nih.gov/pubmed/22547605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1315
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars